Long acting GLP-1 receptor agonist (injectable)
Exenatide extended release 0.8 mg injection once weekly
EXENER_SC_0p8MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.58 (0.01 to 40.13) | 0.57 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.62 (0.01 to 41.46) | 0.64 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.85 (0.05 to 13.17) | 0.48 |